Xinhui Wang

This inventor holds 21 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Cancer Immunotherapy. Top assignees: University of Pittsburgh, The General Hospital Corporation, Health Research, Inc.. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xinhui Wang. Retrieved from https://idiyas.com/inventor/xinhui-wang-txsfm8qd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 4)

% Patents Active = 61.9

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Williamsville, NY (US) (2005 - 2011)
Pittsburg, PA (US) (2013)
Pittsburgh, PA (US) (2013 - 2014)
Boston, MA (US) (2015 - 2021)

Company Filing History:

12 out of 1,960

University of Pittsburgh

patents

5 out of 3,073

The General Hospital Corporation

patents

4 out of 314

Health Research, Inc.

patents

4. 3 out of 1,327

The University of North Carolina at Chapel Hill

patents

5. 1 out of 3

Hauptman-Woodward Medical Research Institute, Inc.

patents

6. 1 out of 519

Sloan-Kettering Institute for Cancer Research

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptor

Monoclonal Antibodies

Cancer Treatment

Tumor Targeting

Immune Response

Antibodies

Peptide Mimics

Basal Breast Carcinoma

Melanoma

Endoplasmin

Sonic Hedgehog Inhibitors

HLA Class II

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428490 - Methods and compositions for chimeric antigen receptor targeting cancer cells (2025-09-30),

2. 11078260 - Antibodies to endoplasmin and their use (2021-08-03),

3. 10881711 - Anti-CSPG4 reagents and methods of treating cancer (2021-01-05),

4. 10519214 - Methods and compositions for chimeric antigen receptor targeting cancer cells (2019-12-31),

5. 10233226 - Methods and compositions for chimeric antigen receptor targeting cancer cells (2019-03-19),

6. 10220091 - Combination treatments with sonic hedgehog inhibitors (2019-03-05),

7. 9902766 - Antibodies to endoplasmin and their use (2018-02-27),

8. 9801928 - Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma (2017-10-31),

9. 9694061 - Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof (2017-07-04),

10. 9340608 - Antibodies to endoplasmin and their use (2016-05-17),

11. 9296811 - Methods for treating a tumor using an antibody that specifically binds HMW-MAA (2016-03-29),

12. 9193796 - Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof (2015-11-24),

13. 9096661 - Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma (2015-08-04),

14. 8771687 - Methods for treating a tumor using an antibody that specifically binds GRP94 (2014-07-08),

15. 8497354 - Antibodies to endoplasmin and their use (2013-07-30),

Title: The Innovations of Xinhui Wang in Cancer Treatment

Introduction

Xinhui Wang, located in Boston, MA, is a distinguished inventor recognized for his significant contributions to the field of cancer research. With a remarkable portfolio of 20 patents, Wang's innovations focus on developing novel antibodies for cancer detection and treatment.

Latest Patents

Among Wang's latest patents is a groundbreaking development involving isolated monoclonal antibodies that bind specifically to endoplasmin. These fully human antibodies are designed to detect and potentially treat tumors expressing endoplasmin, including melanoma, breast cancer, and other malignancies such as lung and renal cancer. Additionally, Wang has developed anti-CSPG4 reagents that target cancer cells expressing the CSPG4 antigen. These innovations include monoclonal antibodies and CAR-T cells aimed specifically at CSPG4 positive cancer cells, embodying significant potential in therapeutic applications.

Career Highlights

Wang's career features key roles at the University of Pittsburgh, part of the Commonwealth System of Higher Education, and Health Research, Inc. His work has propelled forward the understanding of cancer biology and the therapeutic possibilities surrounding monoclonal antibodies.

Collaborations

Wang has collaborated with eminent colleagues such as Soldano Ferrone and Elvira Favoino. These partnerships have fostered advancements within the realm of cancer therapeutics, enhancing the efficacy of cancer treatments through innovative research methods and applications.

Conclusion

In conclusion, Xinhui Wang's contributions to cancer treatment through his patents and research collaborations significantly impact the field of oncology. His work exemplifies the vital role of innovation in the ongoing battle against cancer, marking him as a pivotal figure in the landscape of medical research and therapeutic development.

Profile summary based on public USPTO records.